Document Detail


The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.
MedLine Citation:
PMID:  21513765     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Second-generation antipsychotics (SGAs) increase the risk of metabolic syndrome (MetS). Although ethnicity also contributes to MetS risk, the majority of the studies on the relationship of SGAs to this syndrome come from Western countries, whereas few reports have come from Asian countries, especially regarding patients taking a single SGA. We reviewed the electronic medical records of patients with schizophrenia who received aripiprazole, olanzapine or risperidone monotherapies for at least three months. We evaluated the prevalence of MetS in our sample as well as the indirect standardized prevalence ratio (ISPR) using data from the 4th Korean National Health and Nutrition Examination Survey (KNHNES, 2007). The prevalence of MetS in our sample (n=145) was 31.7%, and the ISPR was 2.09. Male patients had a higher prevalence of MetS than female patients (odds ratio [OR]=4.18, 95% CI=1.93-9.03). The ISPR of male patients was 2.67 and statistically significant, whereas the ISPR of female patients was not significant. In our sample, the frequency of abnormal MetS subcomponents occurred in descending order: increased waist circumference, increased triglyceride levels, decreased HDL-cholesterol levels, elevated blood pressure and elevated fasting blood glucose levels. Patients who received aripiprazole were significantly less likely to have MetS. However, a logistic regression showed that age and sex, but not the type of antipsychotic, its dose or the use of antidepressants, were significantly related to the presence of MetS. There were no statistically significant differences among SGAs in terms of MetS subcomponent abnormalities of after adjusting for age and sex. In conclusion, only male Korean patients with schizophrenia who received a monotherapy of aripiprazole, olanzapine or risperidone for more than three months were more likely to have MetS than the general population.
Authors:
Nam Young Lee; Se Hyun Kim; Dong Chung Jung; Eun Young Kim; Han Young Yu; Ki Hye Sung; Ung Gu Kang; Yong Min Ahn; Yong Sik Kim
Related Documents :
18293385 - Short-term follow-up of patients with sickle cell disease and albuminuria.
6074005 - Alper ca, rosen fs: studies of the in vivo behavior of human c'3 in normal subjects and...
22205275 - Do parkinson's disease patients disclose their adverse events spontaneously?
8296645 - Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in pa...
25469265 - Erg oncoprotein expression in prostate carcinoma patients of different ethnicities.
23649115 - Autonomic dysfunction in multiple sclerosis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-04-14
Journal Detail:
Title:  Progress in neuro-psychopharmacology & biological psychiatry     Volume:  35     ISSN:  1878-4216     ISO Abbreviation:  Prog. Neuropsychopharmacol. Biol. Psychiatry     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-06-06     Completed Date:  2012-01-19     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8211617     Medline TA:  Prog Neuropsychopharmacol Biol Psychiatry     Country:  England    
Other Details:
Languages:  eng     Pagination:  1273-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2011. Published by Elsevier Inc.
Affiliation:
Department of Neuropsychiatry, Seoul National University Hospital, 28 Yongon-Dong, Chongno-Gu, Seoul 110-744, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Age Factors
Antipsychotic Agents / adverse effects*,  therapeutic use
Asian Continental Ancestry Group
Benzodiazepines / adverse effects*,  therapeutic use
Cohort Studies
Databases, Factual
Female
Hospitals, University
Humans
Male
Medical Records
Metabolic Syndrome X / chemically induced,  drug therapy,  epidemiology*
Middle Aged
Piperazines / adverse effects*,  therapeutic use
Quinolones / adverse effects*,  therapeutic use
Republic of Korea / epidemiology
Retrospective Studies
Risperidone / adverse effects*,  therapeutic use
Schizophrenia / drug therapy*,  epidemiology
Sex Factors
Young Adult
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Piperazines; 0/Quinolones; 106266-06-2/Risperidone; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine; 82VFR53I78/aripiprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of carcinogenicity studies of medicinal products for human use authorised via the Europea...
Next Document:  In vitro S100B secretion is reduced by apomorphine: Effects of antipsychotics and antioxidants.